Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018’, provides an overview of the Liver Failure (Hepatic Insufficiency) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency)

- The report reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Liver Failure (Hepatic Insufficiency) therapeutics and enlists all their major and minor projects

- The report assesses Liver Failure (Hepatic Insufficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Liver Failure (Hepatic Insufficiency)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AVM Biotechnology LLC

Celgene Corp

Cell2B Advanced Therapeutics SA

Daewoong Co Ltd

Genentech Inc

Immune Pharmaceuticals Inc

MallInckrodt Plc

Martin Pharmaceuticals Inc

Mina Therapeutics Ltd ...

AVM Biotechnology LLC

Celgene Corp

Cell2B Advanced Therapeutics SA

Daewoong Co Ltd

Genentech Inc

Immune Pharmaceuticals Inc

MallInckrodt Plc

Martin Pharmaceuticals Inc

Mina Therapeutics Ltd

Mylan NV

Novartis AG

PledPharma AB

Promethera Biosciences SA

Synlogic Inc

Takeda Pharmaceutical Co Ltd

Therapure Biopharma Inc

Unicyte AG

Versantis AG

Vital Therapies Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Failure (Hepatic Insufficiency) – Overview

Liver Failure (Hepatic Insufficiency) ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Failure (Hepatic Insufficiency) – Overview

Liver Failure (Hepatic Insufficiency) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Failure (Hepatic Insufficiency) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Failure (Hepatic Insufficiency) – Companies Involved in Therapeutics Development

AVM Biotechnology LLC

Celgene Corp

Cell2B Advanced Therapeutics SA

Daewoong Co Ltd

Genentech Inc

Immune Pharmaceuticals Inc

MallInckrodt Plc

Martin Pharmaceuticals Inc

Mina Therapeutics Ltd

Mylan NV

Novartis AG

PledPharma AB

Promethera Biosciences SA

Synlogic Inc

Takeda Pharmaceutical Co Ltd

Therapure Biopharma Inc

Unicyte AG

Versantis AG

Vital Therapies Inc

Liver Failure (Hepatic Insufficiency) – Drug Profiles

albumin (human) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Failure – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Failure and Alcoholic Hepatitis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWSR-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enasidenib mesylate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-573 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HepaStem – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ImmuneSafe – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipatasertib – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTL-CEBPA – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-100 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resatorvid – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silibinin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP3A4 for Liver Failure – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Failure – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYNB-1020 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trimetazidine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-01 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEN-102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Failure (Hepatic Insufficiency) – Dormant Projects

Liver Failure (Hepatic Insufficiency) – Discontinued Products

Liver Failure (Hepatic Insufficiency) – Product Development Milestones

Featured News & Press Releases

May 14, 2018: PledPharma has completed the recruitment for the clinical trial with Aladote

Mar 29, 2018: Martin Pharmaceuticals Receives FDA Orphan Drug Designation for LIVANTRA

Mar 28, 2018: PledPharma receives European approval of the composition of matter patent for Aladote

Dec 12, 2017: Principal investigator James Dear presents Aladote as a potential new treatment for late stage liver toxicity after paracetamol overdose at Pharmacology conference

Dec 04, 2017: Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018

Oct 04, 2017: Principal investigator of Aladote study James Dear presents calmangafodipir as a potential new treatment for late stage liver toxicity after acetaminophen overdose at liver disease conference

Sep 14, 2017: The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group

Sep 06, 2017: Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors

Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure

Jun 08, 2017: First patient included in PledPharma's clinical trial with Aladote

Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016

Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure

May 17, 2016: COMP Issued a Positive Opinion on Orphan Medicinal Product Designation for VS-01 for The Treatment of Acute Liver Failure

Feb 29, 2016: Versantis Receives Confirmation From The EMA that Its Application for Orphan Drug Designation in Acute Liver Failure Is Valid

Jan 31, 2016: Versantis Initiates the Manufacturing Scale Up of VS-01

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Tables

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by AVM Biotechnology LLC, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Celgene Corp, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Cell2B Advanced Therapeutics SA, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Daewoong Co Ltd, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Genentech Inc, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Immune Pharmaceuticals Inc, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by MallInckrodt Plc, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Martin Pharmaceuticals Inc, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Mina Therapeutics Ltd, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Mylan NV, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Novartis AG, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by PledPharma AB, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Promethera Biosciences SA, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Synlogic Inc, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Therapure Biopharma Inc, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Unicyte AG, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Versantis AG, H1 2018

Liver Failure (Hepatic Insufficiency) – Pipeline by Vital Therapies Inc, H1 2018

Liver Failure (Hepatic Insufficiency) – Dormant Projects, H1 2018

Liver Failure (Hepatic Insufficiency) – Dormant Projects, H1 2018 (Contd..1), H1 2018

Liver Failure (Hepatic Insufficiency) – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Figures

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports